keyboard_arrow_up

Nanotechnologies in Drug Delivery | Newsletter | 27 – 28 April 2015 In London – UK

Nanotechnologies in Drug Delivery Newsletter

Diagnosis and drug delivery for diseases like cancer, cardiovascular and genetic ailments has always been a concern. In recent years, however, new strides and developments in the nano-medicine market have facilitated more effective diagnosis and drug delivery for diseases.
Not only can these diseases now be studied better but it will also help us in making informed decisions producing better cures. The nano-medicine market is on a steady growth and with a compound annual growth rate (CAGR) of 12.5% from 2011; the market size will reach to $130.9 billion by 2016.
  • Nanotechnology in Drug Delivery - Cancer
Many researchers attach ethylene glycol molecules to nanoparticles that deliver therapeutic drugs to cancer tumors. The ethylene glycol molecules stop white blood cells from recognizing the nanoparticles as foreign materials, allowing them to circulate in the blood stream long enough to attach to cancer tumors. For more information about the article, visit Understanding nano.

Nanotechnologies in Drug Delivery Congress to be held on 27 – 28 April 2015 In London – UK has a wide range of topics on drug delivery for cancer therapies. Some of these topics are:

  • The role of Nanomedicine and Targeted Medicine for Personalised Medicine
  • European Medical Devices Regulation of Nanotechnologies in Drug Delivery
  • Theranostics: Combining Diagnostics and Delivery in a Single Device
  • Mesoporous silica nanoparticles as a drug delivery system for anticancer therapy
  • Polyamine-coated carbon nanotubes allow efficient microRNAs delivery in endothelial cells
  • Molecular imaging modalities – Revolutionizing the way we look inside human body

Presenting these topics will be organizations like:


  • Nanotechnology - enabled drug delivery in HIV therapy

“Nanotechnology-based HIV drug delivery has attracted recent attention within academia with many technologies in early stage evaluation for improving oral bioavailability or targeting HIV-infected cells and tissues. Interest has been significantly accelerated recently by the entry of long-acting Nano formulations into human trials.

These Nano formulations developed by Janssen Pharmaceuticals and ViiV Healthcare are able to sustain therapeutic concentrations in blood for over 1 month from a single intramuscular depot injection.” - Prof. Andrew Owen, Chair - British Society of Nanomedicine, Professor of Pharmacology, University of Liverpool.

One of the key speakers at the Nanotechnologies in Drug Delivery Congress, Prof. Owen believes nanotechnology - enabled drug delivery will positively influence future treatments of HIV patients. We recently did a pre-event interview with him; know more about his topic herehttp://www.mnmconferences.com/nanotechnologies.html?utm_source=pitch&utm_medium=referral&utm_campaign=NDD.


  • Sponsors at the  Nanotechnologies in Drug Delivery Congress


  • Other industry events

Cancer Diagnosis and Therapy Congress will be held on 3 - 4 September 2015 in London, UK.

Some of our confirmed speakers will be representing organizations like:

  • European Society of Surgical Oncologists
  • University of Sussex
  • Oxford Institute for Radiation Oncology
  • Imperial College London
  • Wolfgang Goethe – University
  • Celgene
  • University of Manchester
  • Guangzhou East Cancer Hospital
  • University of Leicester
  • Agenus & 4-Antibody AG
  • King’s College London

For more information please feel free to contact us on ajay.nimbalkar@mnmconferences.com

Warm Regards,

Ajay Nimbalkar

Assistant Manager | Web Marketing
MarketsandMarkets Conferences